(Alliance News) - Yourgene Health PLC on Tuesday said it is on track to launch its new non-invasive prenatal test on the Illumina platform in early 2020.
YourGene and Illumina agreed to a licence and supply deal in its financial year ended March 31, concluding its patent litigation issues with Illumina, with YourGene agreeing to pay royalties.
Speaking at molecular diagnostics firm's annual general meeting, Chair Adam Reynolds will also note the Wednesday launch of a "new chemo-toxicity diagnostic assay" for DPYD, YourGene's first oncology product.
DPYD is a test which identifies patients who have DPD deficiency, which can cause severe or even lethal side effects in chemotherapy patients.
The chair will note that the integration of Elucigene - acquired in April 2018 - is going well and it has found synergy savings in excess of GBP500,000.
"The balance sheet has been transformed over the past twelve months and with an experienced and motivated executive management team in place, supported by the additional high calibre Non-executives that have joined the board I am confident of the growth strategy we have set ourselves to deliver enhanced shareholder value," said Reynolds.
Shares in Yourgene were up 2.7% at 11.55 pence in London on Tuesday afternoon.
